RT Journal Article
SR Electronic
A1 Kuznar, Wayne
T1 Treatment Paradigms for MPNs Continue to Evolve
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 55
SP 28
OP 30
DO 10.1177/1559897714568643
UL http://mdc.sagepub.com/content/14/55/28.abstract
AB Ten years after the identification of the JAK2V617F mutation in most patients with myeloproliferative neoplasms, the understanding of the pathophysiology and genomic landscape of MPNs has evolved. The enhanced understanding and recognition of the impact of symptomatic burden on risk have led to targeted therapies and new treatment paradigms.